| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 08/30/2001 | CA2400485A1 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 08/30/2001 | CA2400435A1 Novel compounds |
| 08/30/2001 | CA2400434A1 Novel compounds |
| 08/30/2001 | CA2400293A1 Novel compounds |
| 08/30/2001 | CA2400215A1 Hla binding peptides and their uses |
| 08/30/2001 | CA2400099A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | CA2400040A1 Integrin antagonists |
| 08/30/2001 | CA2399298A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2399211A1 Foam-forming wound dressing |
| 08/30/2001 | CA2398275A1 Human polynucleotides, polypeptides, and antibodies |
| 08/30/2001 | CA2396960A1 Novel use of phenylheteroalkylamine derivatives |
| 08/29/2001 | EP1127884A1 Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them |
| 08/29/2001 | EP1127883A2 Oxamides as IMPDH inhibitors |
| 08/29/2001 | EP1127580A2 Method of increasing the bioavailability and tissue penetration of azithromycin |
| 08/29/2001 | EP1127577A2 Ligand for the c-kit receptor and methods of use thereof |
| 08/29/2001 | EP1127572A2 Use of flavones for treating cycloxygenase-2 mediated diseases |
| 08/29/2001 | EP1127168A2 Method for determining the susceptibility to developing sepsis and therapeutics for the treatment of sepsis |
| 08/29/2001 | EP1127151A2 Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors |
| 08/29/2001 | EP1127134A1 Rotavirus subunit vaccine |
| 08/29/2001 | EP1127132A1 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| 08/29/2001 | EP1127110A1 Modified exosomes and uses |
| 08/29/2001 | EP1127109A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 08/29/2001 | EP1127107A1 Methods for the production of tcr gamma delta t cells |
| 08/29/2001 | EP1127067A2 Inhibition of transglutaminase-mediated microbial interaction with a mammalian host |
| 08/29/2001 | EP1127065A2 $i(chlamydia) antigens and corresponding dna fragments and uses thereof |
| 08/29/2001 | EP1127058A1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 08/29/2001 | EP1127057A1 Naphthyridine compounds and thier azaisosteric analogues as antibacterials |
| 08/29/2001 | EP1127054A1 Novel inhibitors of impdh enzyme |
| 08/29/2001 | EP1126876A2 Adjuvant systems and vaccines |
| 08/29/2001 | EP1126875A2 Pharmaceutically active composition and dispensing device |
| 08/29/2001 | EP1126874A2 Multicomponent meningococcal vaccine |
| 08/29/2001 | EP1126865A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 08/29/2001 | EP1126859A2 Blood leucocyte apheresis for treatment of disease |
| 08/29/2001 | EP1126852A1 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 08/29/2001 | EP1126849A1 Heterocyclic potassium channel inhibitors |
| 08/29/2001 | EP1126847A1 Method for improving the pharmacokinetics of tipranavir |
| 08/29/2001 | EP1126845A2 New use of immunosuppressants for mmp-mediated diseases |
| 08/29/2001 | EP1126843A1 Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
| 08/29/2001 | EP1126839A1 Substituted phenethylsulfones and method of reducing tnf alpha levels |
| 08/29/2001 | EP1126838A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 08/29/2001 | EP1126837A1 Fulvic acid and its use in the treatment of various conditions |
| 08/29/2001 | EP1126836A1 Benzamide potassium channel inhibitors |
| 08/29/2001 | EP1126832A2 Conductance of improperly folded proteins through the secretory pathway |
| 08/29/2001 | EP0904299B1 Synthetic polysaccharides, method for preparing same and pharmaceutical compositions containing said polysaccharides |
| 08/29/2001 | EP0851866B1 Therapeutic compounds |
| 08/29/2001 | EP0828741B1 Spirocyclic and bicyclic diazinyl and carbazinyl oxazolidinones |
| 08/29/2001 | EP0825983B1 Process for the preparation of 2,2'-bipyrrolyl-pyrromethene (prodigiosins) derivatives |
| 08/29/2001 | EP0751709B1 Use of bcl-2 for the manufacture of medicaments for the therapeutic treatment and prevention of diseases |
| 08/29/2001 | EP0736030B1 Tetrahydrofuran antifungals |
| 08/29/2001 | EP0687181B1 Use of thymosin for treating hepatitis c in non-responders to interferon treatment |
| 08/29/2001 | EP0618925B1 Antisense oligonucleotides |
| 08/29/2001 | CN1310716A Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 08/29/2001 | CN1310715A Polymorph of ritonavir |
| 08/29/2001 | CN1310626A Hybrid polypeptides with enhanced pharmacokinetic properties |
| 08/29/2001 | CN1310179A Oxamide being as IMPDH inhibitor |
| 08/29/2001 | CN1310175A Process for producing bis (4-amino-1-pyridine) paraffins |
| 08/29/2001 | CN1310001A Combined Chinese and Western medicine for treating chronic bronchitis in catabasis |
| 08/29/2001 | CN1309993A Compounding process of phthisis treating medicine |
| 08/29/2001 | CN1309970A Application of uridine phosphorylase inhibitor and composition containing the same |
| 08/29/2001 | CN1309966A Rifapentine or Rifampicin microemulsion and suspension perfusate and injection and their preparation |
| 08/29/2001 | CN1070192C Thiopyridine for use in control of helicobacter bacteria |
| 08/29/2001 | CN1070180C Pharmaceutical formulations containing polythiourea and its using method |
| 08/29/2001 | CN1070054C Medicine for treating syphilopathy |
| 08/29/2001 | CN1070050C Medicinal plaster for external use |
| 08/29/2001 | CA2337661A1 Stabilized granulocyte colony stimulating factor |
| 08/28/2001 | US6281376 Therapeutic compound—fatty acid conjugates |
| 08/28/2001 | US6281367 Process for the synthesis of HIV protease inhibitors |
| 08/28/2001 | US6281363 Antiinflammatory agents; antiarthritic agents; autoimmune disorders |
| 08/28/2001 | US6281352 Antiinflammatory agents |
| 08/28/2001 | US6281342 Pradimicin compounds |
| 08/28/2001 | US6281336 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| 08/28/2001 | US6281226 Pleuromutilin derivatives as antimicrobials |
| 08/28/2001 | US6281210 Benzoic acid esters of oxazolidinones having a hydroxyacetylpiperazine substituent |
| 08/28/2001 | US6281000 Dna fragment cloning into genome of recombinant adenoviral plasmid vector; human gene therapy |
| 08/28/2001 | US6280991 Engineered cytotoxic ribonclease |
| 08/28/2001 | US6280978 Methods and compositions for use in spliceosome mediated RNA trans-splicing |
| 08/28/2001 | US6280974 Nucleotide sequence coding viral protein; for use as diagnostic tool in detection of viral diseases |
| 08/28/2001 | US6280959 Zinc chelated cell surface receptor ligands for use as agonist of dimeric cell surface receptors; for example, 2-bis(2,5-bis(2-benzimidazolylimino)-3A,6A-diphenyl-1,2,3,3a, 4,5,6,6a-octahydroimidazo(4,5-d)imidazole-N,N')-zinc(II) |
| 08/28/2001 | US6280953 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 08/28/2001 | US6280777 Soya extract, process for its preparation and pharmaceutical composition |
| 08/28/2001 | US6280741 Administering to horse effective amount of haemophilus somnus vaccine containing killed bacterin of haemophilus to treat for navicular disease |
| 08/28/2001 | US6280740 Formulations of recombinant papillomavirus vaccines |
| 08/28/2001 | US6280738 Non-IgA Fc binding forms of the group B streptococcal β antigens |
| 08/28/2001 | US6280735 Polypeptides of riboflavin specific deaminase family |
| 08/28/2001 | US6280734 Simian-human HAV having a chimeric 2C protein |
| 08/28/2001 | US6280732 Administering intracerebrally al-1 immunoadhesin comprising mature al-1 polypeptide having specified amino acid sequence in amount effective to activate autophosphorylation of rek7 |
| 08/28/2001 | US6280726 Used in treating bacterial infections |
| 08/28/2001 | CA2333930A1 Dna sequence encoding the specific and antigenic outer membrane protein of s amonella typhi |
| 08/28/2001 | CA2322579C Gelling ophthalmic compositions containing xanthan gum |
| 08/28/2001 | CA2203443C Hepatitis c virus asialoglycoproteins |
| 08/28/2001 | CA2107552C Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
| 08/28/2001 | CA2101572C Benzoxazinones as inhibitors of hiv reverse transcriptase |
| 08/28/2001 | CA2096112C Hexapeptides deriving from aglucoteicoplanin and a process for preparing them |
| 08/28/2001 | CA2041331C Nojirimycin derivatives |
| 08/28/2001 | CA2017252C Retroviral protease inhibiting compounds |
| 08/28/2001 | CA2015996C Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals |
| 08/25/2001 | CA2337923A1 Peptide antibiotics |
| 08/24/2001 | CA2337588A1 Oxamides as impdh inhibitors |
| 08/23/2001 | WO2001061013A1 Haemophilus influenza outer membrane protein and use thereof in vaccination |
| 08/23/2001 | WO2001060975A2 Gene disruption methodologies in fungi for drug target discovery |